



## (51) International Patent Classification:

A61K 31/4015 (2006.01) A61K 48/00 (2006.01)  
A61K 39/395 (2006.01)

## (21) International Application Number:

PCT/US2018/018181

## (22) International Filing Date:

14 February 2018 (14.02.2018)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/464,557 28 February 2017 (28.02.2017) US

(71) Applicant: UNIVERSITY OF MASSACHUSETTS  
[US/US]; One Beacon Street, 31ST Floor, Boston, Massachusetts 02108 (US).

## (72) Inventors: GREEN, Michael R.; 368 Green Street, Boylston, Massachusetts 01505 (US). FANG, Minggang; 7 Jones Street, Apt. 2, Worcester, Massachusetts 01604 (US).

## (74) Agent: DEYOUNG, Janice Kugler; Fish &amp; Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## (54) Title: GENETIC AND PHARMACOLOGICAL TRANSCRIPTIONAL UPREGULATION OF THE REPRESSED FXN GENE AS A THERAPEUTIC STRATEGY FOR FRIEDREICH ATAXIA




FIG. 1H

(57) Abstract: Methods of treating subjects having disorders associated with mutations in the FXN gene and/or having reduced expression of frataxin protein, e.g., Friedreich ataxia (FA). Generally, the methods include administering a therapeutically effective amount of an agent that increases expression of frataxin protein as described herein, e.g., an inhibitor of a FXN Repressing Factor (FXN-RF).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*

# Genetic and Pharmacological Transcriptional Upregulation of the Repressed *FXN* Gene as a Therapeutic Strategy for Friedreich Ataxia

## CROSS REFERENCE TO RELATED APPLICATION

5           This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Application No. 62/464,557 filed February 28, 2017. The entire contents of the foregoing are incorporated herein by reference.

## TECHNICAL FIELD

10           Described herein are methods of treating subjects with disorders associated with mutations in the *FXN* gene and that have reduced expression of frataxin protein, e.g., Friedreich ataxia (FA). Generally, the methods include administering a therapeutically effective amount of an agent that increases expression of frataxin protein as described herein, e.g., an inhibitor of a FXN Repressing Factor (FXN-RF).

## BACKGROUND

15           Friedreich ataxia (also called Friedreich's ataxia) (FA) is an autosomal recessive inherited disease that causes progressive damage to the nervous system, resulting in movement problems. FA is the most common genetic form of ataxia, and occurs in approximately 1 in 50,000 people. Symptoms typically first appear at 5-15 years of age, followed by progressive neurodegeneration. Typically, within 10 years following the  
20           onset of symptoms, the patient is wheelchair bound. The disease affects multiple organs, including the heart and pancreas. Patients have a shortened life expectancy, with most patients dying of cardiac failure. To date, there is no effective therapy for FA.

          FA is caused by a GAA•TTC triplet repeat expansion in the first intron of the *FXN* gene (also called the triplet repeat expansion (TRE)-*FXN* gene NCBI RefSeqGene  
25           NG\_008845.2), which encodes a protein called frataxin, a ubiquitous, nuclear-encoded mitochondrial protein (Campuzano et al. 1996, *Science* 271:1423-1427). Unaffected individuals have 6–30 GAA•TTC repeats, whereas affected individuals have approximately 70-1000 repeats (Sharma et al. 2004, *Ann Neurol* 56:898-901; Pandolfo  
30           2008, *Arch Neurol* 65:1296-1303). The effect of the GAA•TTC repeat expansion mutation is to repress *FXN* expression at the level of transcription. The extent of *FXN*

repression is directly related to the length of the GAA•TTC repeat; age of onset and disease severity are also correlated with the length of the GAA•TTC repeat (Chutake et al. 2014, *Ann Neurol* 76:522-528). Importantly, the TRE-*FXN* gene encodes functional frataxin, albeit at reduced levels. Transcriptional upregulation of the TRE-*FXN* gene is a potential therapeutic strategy for treating FA.

## SUMMARY

Our work has identified a number of factors including biologicals and small molecule inhibitors that increase transcription of the TRE-*FXN* gene. For example, described herein are compounds that increase transcription of the TRE-*FXN* gene, which has immediate therapeutic implications.

Provided herein are methods for treating a subject having a disorder associated with a mutation in the *FXN* gene and having reduced expression of frataxin protein. The methods include administering to the subject a therapeutically effective amount of a small molecule inhibitor of a *FXN* Repressing Factor (*FXN*-RF), e.g., selected from the group consisting of DNMT3A, DNMT3B, SETDB1, EZH2, EED, EHMT2/G9a, RING1B/RNF2, KDM5A, KDM5D, HDAC2, HDAC5, and SIRT7. Exemplary small molecules include molecules shown in Table 1 or Figs. 7A-7F.

Alternatively, or in addition, the methods can include administering to the subject a therapeutically effective amount of an inhibitory nucleic acid that targets and specifically reduces expression of a *FXN* Repressing Factor (*FXN*-RF) selected from the group consisting of DNMT3A, DNMT3B, EED, EZH2, SETDB1, EHMT2/G9a, RING1B/RNF2, KDM5A, KDM5D, HDAC2, HDAC5, and SIRT7. In some embodiments, the inhibitory nucleic acid is a small interfering RNA, small hairpin RNA, or antisense oligonucleotide.

Also provided herein is the use of a small molecule inhibitor of a *FXN* Repressing Factor (*FXN*-RF) selected from the group consisting of EZH2, SETDB1, DNMT3A, DNMT3B, SETDB1, EED, EHMT2/G9a, RING1B/RNF2, KDM5A, KDM5D, HDAC2, HDAC5, and SIRT7, optionally a molecule shown in Table 1 or Figs. 7A-7F, for treating a subject having a disorder associated with a mutation in the *FXN* gene and having reduced expression of frataxin protein. Also provided is the use of an inhibitory nucleic acid that targets and specifically reduces EZH2, SETDB1, DNMT3A, DNMT3B, SETDB1, EED, EHMT2/G9a, RING1B/RNF2, KDM5A, KDM5D, HDAC2, HDAC5, and SIRT7, e.g., a small interfering RNA, small hairpin RNA, or antisense

oligonucleotide, for treating a subject having a disorder associated with a mutation in the FXN gene and having reduced expression of frataxin protein.

In some embodiments, the subject has Friedreich ataxia (FA).

In some embodiments, the small molecule is an inhibitor as shown in Table 1,  
 5 e.g., an inhibitor of EZH2 (e.g., EPZ6438, GSK126, F2880-2566; F5564-0146; F6235-0533; or F3407-3748); an inhibitor of SETDB1 and EHMT2 (e.g., chaetocin); an inhibitor of KDM5A (e.g., F3222-4242; F3358-0326; or F3385-1519) or KDM5D; an HDAC inhibitor (e.g., F0307-0365; F3407-0197; F6196-0976; F3095-0357; LMK235; PCI-24781; or trichostatin A (TSA)); an inhibitor of SUV39H1 (e.g., F2470-0099;  
 10 F2880-1734; or F3222-4478); an inhibitor of DNMT3A or DNMT3B (e.g., F2578-0281; F3258-0176; or F3342-0131); or an inhibitor of SIRT7 (e.g., F2721-0219; F3220-0531; F3220-0613; F3319-0778; or F3385-2786). In place of an inhibitor of EZH2, other inhibitors of components of the PRC2 complex can be used, e.g., inhibitors of EED

In some embodiments, the small molecule inhibitors of FXN-RF is not an HDAC  
 15 inhibitor, or is not an inhibitor of HDAC1 or HDAC3, or is not RGFP109 as described in Plasterer et al., PLoS One. 2013; 8(5): e63958, and/or is not compounds 106 (N1-(2-aminophenyl)-N7-p-tolylheptanediamide), 136 (N-(6-(2-amino-4-fluorophenylamino)-6-oxyhexyl)-4-methylbenzamide), or 109 (N-(6-(2-aminophenylamino)-6-oxyhexyl)-4-methylbenzamide) described in Rai et al., PLoS One. 2010; 5(1): e8825 and Sandi et al.,  
 20 Neurobiol Dis. 2011 Jun; 42(3): 496–505.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The  
 25 materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

Other features and advantages of the invention will be apparent from the  
 30 following detailed description and figures, and from the claims.

## DESCRIPTION OF DRAWINGS

FIGs. 1A-1C show identification of epigenetic repressors that promote repression of *FXN* in FA induced pluripotent stem cells (iPSCs). FIG 1A shows a quantitative RT-

PCR (qRT-PCR) analysis monitoring expression of the TRE-*FXN* gene in an iPSC line (GM23404) derived from a patient with FA (hereafter called FA(GM23404) iPSCs) expressing one of two unrelated shRNAs targeting a set of 33 epigenetic repressors. The results were normalized to that obtained with a control non-silencing (NS) shRNA, which was set to 1. The results identified 10 *FXN* repressing factors (FXN-RFs). FIG. 1B shows an immunoblot analysis showing frataxin levels in FA(GM23404) iPSCs expressing an NS or a FXN-RF shRNA. Frataxin levels in normal iPSCs are shown.  $\alpha$ -tubulin (TUBA) was monitored as a loading control. The results allow us to show that knockdown of each FXN-RF increases frataxin to levels comparable to that observed in normal iPSCs. FIG. 1C shows qRT-PCR analysis monitoring *FXN* transcription in a second FA iPSC line, FA(GAA-intact) iPSCs. The results were normalized to that obtained with isogenic FA(GAA-excised) iPSCs, which was set to 1.

FIGs. 1D-1G show that FXN-RFs associate with the first intron of the TRE-*FXN* gene and are sequentially recruited in an ordered pathway. FIG. 1D shows chromatin immunoprecipitation (ChIP) analysis monitoring binding of FXN-RFs to the first intron of the TRE-*FXN* gene, or as a negative control the promoter of the *APRT* gene, in FA(GM23404) and normal iPSCs. The results were normalized to that obtained with IgG, which was set to 1. FIGs. 1E-1F show ChIP analysis monitoring binding of representative FXN-RFs in FA(GM23404) iPSCs following knockdown of each of the other FXN-RFs. FIG. 1G shows a schematic of a hypothesized ordered pathway of FXN-RF recruitment. Data are represented as mean  $\pm$  SD (n=3 technical replicates of a representative experiment (out of 3 independent experiments)). \*P<0.05, \*\*P<0.01.

FIGs. 1H-1K show transcriptional upregulation of TRE-*FXN* by small molecule FXN-RF inhibitors. FIG. 1H shows qRT-PCR analysis monitoring *FXN* transcription in FA(GM23404) iPSCs treated with EPZ6438 (0.2  $\mu$ M), GSK126 (0.1  $\mu$ M), chaetocin (0.1  $\mu$ M), LMK235 (0.5  $\mu$ M), PCI-24781 (0.2  $\mu$ M), TSA (10 nM), KDM5Ai (1  $\mu$ M) or, as a control, DMSO. The results were normalized to that obtained in normal iPSCs, which was set to 1. FIG. 1I shows qRT-PCR analysis monitoring *FXN* transcription in FA(GM23404) iPSCs treated with GSK126 (0.01, 0.1, 1  $\mu$ M), TSA (1, 10, 100 nM) or KDM5Ai (0.1, 1, 10  $\mu$ M). The results were normalized to that obtained with DMSO, which was set to 1. FIG. 1J shows the results of immunoblot analysis showing frataxin levels in FA(GM23404) iPSCs treated with a small molecule FXN-RF inhibitor. FIG. 1K shows qRT-PCR analysis monitoring *FXN* transcription in FA(GAA-intact) iPSCs. Data

are represented as mean  $\pm$  SD (n=3 technical replicates of a representative experiment (out of 3 independent experiments)). \*P<0.05, \*\*<0.01.

FIGs. 2A-2F show that FXN-RFs also mediated epigenetic repression of the TRE-*FXN* gene in post-mitotic FA neurons. FIG. 2A is a micrograph showing morphology of neurons derived from FA(GM23404) iPSCs, by immunofluorescence with an anti-TUJ1 antibody. FIG. 2B shows the percentage of TUJ1-positive (left) and phosphorylated histone H3 at serine 10 (pH3)-positive (right) in FA iPSCs and FA neurons. FIG. 2C shows qRT-PCR analysis monitoring *FXN* transcription in FA neurons expressing an shRNA targeting an FXN-RF. The results were normalized to that obtained in normal neurons, which was set to 1. These results include normal neurons as controls, to show that upon reactivation, *FXN* levels increase to levels comparable to that observed in normal neurons. FIG. 2D shows immunoblot analysis showing frataxin levels in FA neurons expressing an NS or FXN-RF shRNA. Frataxin levels in normal neurons are shown. FIG. 2E shows qRT-PCR analysis monitoring *FXN* transcription in FA neurons treated with small molecule FXN-RF inhibitors. FIG. 2F shows immunoblot analysis showing frataxin levels in FA neurons treated with a small molecule FXN-RF inhibitor. Data are represented as mean  $\pm$  SD (n=3 technical replicates of a representative experiment (out of 3 independent experiments)). \*P<0.05, \*\*<0.01.

FIGs. 3A-3C show inhibition of FXN-RFs can ameliorate characteristic mitochondrial defects of FA post-mitotic neurons. FIG. 3A shows a representative flow cytometry analysis of FA neurons expressing a non-silencing (NS), EZH2 or HDAC5 shRNA. The neurons were harvested, stained with MitoSOX and analyzed by flow cytometry. FIG. 3B shows quantification of flow cytometry analysis of normal neurons and FA neurons expressing an FXN-RF shRNA or treated with a small molecule FXN-RF inhibitor and stained with MitoSOX. The results were normalized to that obtained with a control NS shRNA, which was set to 1. FIG. 3C shows analysis of oxygen consumption rate in normal neurons and FA neurons expressing an FXN-RF shRNA or treated with a small molecule FXN-RF inhibitor. Data are represented as mean  $\pm$  SD (n=3 technical replicates of a representative experiment (out of 3 independent experiments)). \*P<0.05, \*\*<0.01.

FIGs. 4A-4E show that FXN-RFs also mediate epigenetic repression of the TRE-*FXN* gene in FA cardiomyocytes. FIG. 4A shows the results of analysis of micrographs showing cardiac troponin T (cTNT)- or sarcomeric actinin (SA)-positive cardiomyocytes

(CMCs) derived from FA(GM23404) iPSCs. Shown is the percentage of cells staining positive for cTNT or SA in FA iPSCs or FA CMCs. FIG. 4B shows qRT-PCR analysis monitoring *FXN* transcription in FA CMCs expressing an shRNA targeting an FXN-RF. The results were normalized to that obtained in normal CMCs, which was set to 1. FIG. 4C shows immunoblot analysis showing frataxin levels in FA CMCs expressing an NS or FXN-RF shRNA. Frataxin levels in normal CMCs are shown. FIG. 4D shows qRT-PCR analysis monitoring *FXN* transcription in FA CMCs treated with small molecule FXN-RF inhibitors. FIG. 4E shows immunoblot analysis showing frataxin levels in FA CMCs treated with a small molecule FXN-RF inhibitor. Data are represented as mean  $\pm$  SD (n=3 technical replicates of a representative experiment (out of 3 independent experiments)). \*P<0.05, \*\*<0.01

FIGs. 5A-5B show that inhibition of FXN-RFs can ameliorate the characteristic mitochondrial defects of FA cardiomyocytes. FIG. 5A shows quantification of flow cytometry analysis of normal cardiomyocytes (CMCs) and FA CMCs expressing an FXN-RF shRNA or treated with a small molecule FXN-RF inhibitor and stained with MitoSOX. The results were normalized to that obtained with a control NS shRNA, which was set to 1. FIG. 5B shows analysis of oxygen consumption rate in normal CMCs and FA CMCs expressing an FXN-RF shRNA or treated with a small molecule FXN-RF inhibitor. Data are represented as mean  $\pm$  SD (n=3 technical replicates of a representative experiment (out of 3 independent experiments)). \*P<0.05, \*\*<0.01.

FIG. 6 shows identification of additional small molecule FXN-RF inhibitors from a small-scale pilot screen. qRT-PCR analysis monitoring *FXN* transcription in FA(GM23404) iPSCs treated with 70 small molecule compounds that are predicted be inhibitors of nine of the FXN-RFs. The results were normalized to that obtained with DMSO, which was set to 1. H3K9-MTs, H3K9 methyltransferases. Data are represented as mean  $\pm$  SD (n=3 technical replicates of a representative experiment (out of 3 independent experiments)). \*P<0.05, \*\*P<0.01.

FIGs. 7A-7E show the structures of exemplary predicted inhibitors of EZH2 (F2880-2566; F5564-0146; F6235-0533; and F3407-3748, FIG 7A); H3K9 methyltransferases (F2470-0099; F2880-1734; and F3222-4478, FIG 7B); KDM5s, e.g., KDM5A or 5D (F3222-4242; F3358-0326; and F3385-1519, FIG 7C); HDACs (F0307-0365; F3407-0197; F6196-0976; and F3095-0357, FIG 7D); and DNMTs (F2578-0281; F3258-0176; and F3342-0131, FIG 7E).

FIG 7F shows the structure of exemplary predicted inhibitors of SIRT5, e.g., SIRT5 or SIRT7, including F2721-0219; F3220-0531; F3220-0613; F3319-0778; and F3385-2786.

### DETAILED DESCRIPTION

5 FA is caused by transcriptional repression of the TRE-*FXN* gene, resulting in decreased levels of frataxin. The deficiency of frataxin is associated with several indicators of mitochondrial dysfunction, including iron accumulation in the mitochondria, impairment of iron-sulfur (Fe-S) cluster-containing enzymes, increased sensitivity to oxidative stress, and deficits of respiratory chain complex activities (Bradley  
10 et al. 2000, *Hum Mol Genet* 9:275-282; Foury and Cazzalini 1997, *FEBS Lett* 411:373-377; Waldvogel et al. 1999, *Ann Neurol* 46:123-125; Koeppen et al. 2007, *Acta Neuropathol* 114:163-173; Wong et al. 1999, *Hum Mol Genet* 8:425-430).

Recent studies have shown that several repressive epigenetic marks, comprising chemical modifications of DNA and histones, are associated with repression of the TRE-  
15 *FXN* gene, including increased DNA methylation, histone H3 lysine 27 trimethylation (H3K27me3), histone H3 lysine 9 trimethylation (H3K9me3), and histone H4 lysine 20 trimethylation (H4K20me3) (reviewed in Sandi et al. 2014, *Front Genet* 5:165). Conversely, there is a decrease in activating marks, including histone (H2A/2B/3/4) acetylation and histone H3 lysine 4 trimethylation (H3K4me3).

20 Transcriptional upregulation of the TRE-*FXN* gene is a potential therapeutic strategy for treating FA. An attractive feature of this approach is that it is based on correcting the root cause of the disease, the decreased levels of frataxin, rather than some secondary, downstream consequence of the frataxin deficiency. Notably, the level of frataxin in FA patients is only a few-fold lower than that in asymptomatic carriers, who  
25 harbor one TRE-*FXN* allele and one normal *FXN* allele (Pianese et al. 2004, *J Neurol Neurosurg Psychiatr* 75:1061-1063). Thus, even a modest increase in transcription of the TRE-*FXN* gene is likely to be therapeutically beneficial.

The epigenetic regulators responsible for depositing repressive marks or for removing activating marks are attractive targets to upregulate transcription of the TRE-  
30 *FXN* gene. Indeed, previous studies have evaluated histone deacetylase (HDAC) inhibitors as potential FA therapeutics (Rai et al. 2010, *PLoS One* 5:e8825; Sandi et al. 2011, *Neurobiol Dis* 42:496-505; Plasterer et al., *PLoS One*. 2013; 8(5): e63958). Although these HDAC inhibitors upregulate transcription of the TRE-*FXN* gene and

ameliorate disease phenotypes in an FA mouse model, they suffer from nonspecificity and toxicity. To date, there has been no systematic attempt to identify additional negative epigenetic regulators of *FXN*, which may provide more desirable therapeutic targets.

As demonstrated herein, there are a number of negative epigenetic regulators whose pharmacological inhibition will lead to increased transcription of the TRE-*FXN* gene, resulting in increased frataxin levels and decreased disease symptomatology. The present methods include inhibiting, e.g., either through inhibitory nucleic acids (e.g., RNA interference (RNAi)-mediated knockdown) or small molecule inhibitors, these epigenetic repressors of the TRE-*FXN* gene. In some embodiments, the inhibition of these repressors increases transcription of the TRE-*FXN* gene at least 2–6-fold or more.

### Methods of Treatment

The methods described herein include methods for the treatment of disorders associated with mutations in the *FXN* gene and/or that have reduced expression of frataxin protein (but wherein the frataxin protein itself is functional). In some embodiments, the disorder is Friedreich ataxia (FA). Generally, the methods include administering a therapeutically effective amount of an agent that increases levels of frataxin protein as described herein, to a subject who is in need of, or who has been determined to be in need of, such treatment. Methods known in the art can be used to diagnose or identify a subject as having a disorder associated with a mutation in the *FXN* gene that reduces expression of the frataxin protein, e.g., sequencing or identification of the presence of trinucleotide repeat expansion (e.g., using a commercially available assay such as the Friedreich ataxia (FXN) Repeat Expansion Test (Athena Diagnostics)); a quantitative immunoassay to measure frataxin levels, e.g., as described in Plasterer et al., PLoS One. 2013; 8(5): e63958, or a lateral flow test as described in Willis et al., Mol Genet Metab. 2008 Aug; 94(4): 491–497 or commercially available kits such as the dipstick kit from abcam (ab109881); MRI to detect atrophy of the cervical spinal cord with minimal evidence of cerebellar atrophy; transcranial sonography for assessment of both cerebellar and noncerebellar abnormalities, e.g., dentate hyperechogenicity. Typically, subjects present with gait ataxia (e.g., tabetocerebellar gait), with ataxia progressing to the legs, trunk, and arms; development of tremors; titubation; and trembling. To determine severity, any of three scales can be used, e.g., The International Cooperative Ataxia Rating Scale (ICARS), the Friedreich Ataxia Rating Scale (FARS),

and the Scale for the Assessment and Rating of Ataxia (SARA), see, e.g., Bürk et al., J. Neurochem. 126 Suppl. 1:118-24 (2013).

As used in this context, to “treat” means to ameliorate at least one symptom of the disorder associated with mutations in the *FXN* gene that reduce expression. FA is an autosomal recessive neurodegenerative disorder that results in progressive gait and limb ataxia with associated limb muscle weakness, absent lower limb reflexes, extensor plantar responses, dysarthria, and decreased vibratory sense and proprioception, as well as cardiac manifestations including cardiac dysfunction and heart failure; visual field defects; and diabetes. Thus, a treatment can result in a reduction in the severity of these deficits or a reduction in the rate of decline or degeneration. Administration of a therapeutically effective amount of a compound described herein for the treatment of a condition associated with mutations in the *FXN* gene that reduce expression, e.g., FA, will result in improvement in one or more symptoms, e.g., reduction in the severity or rate of decline in gait and limb ataxia, limb muscle weakness, deficits in lower limb reflexes, extensor plantar responses, dysarthria, and vibratory sense and proprioception, and a return or approach to normal gait and limb movements, a return or approach to normal muscle strength and reflexes, a return or approach to normal (flexor) plantar responses, reduced dysarthria/improved speech, and a return or approach to normal vibratory sense and proprioception, as well as a reduction in the severity or risk of cardiac dysfunction and/or heart failure or diabetes. In some embodiments, the treatment results in decreased morbidity or mortality, e.g., a delayed loss of ambulation, an increased life span (average age of death is  $37.7 \pm 14.4$  years, range 21-69, Harding et al., J. Med Genet. 18(4):285-7 (1981)) and/or an improved quality of life.

### **Therapeutic Agents**

Agents that increase expression of frataxin protein as described herein include inhibitors of DNMT3A, DNMT3B, EED, EZH2, SETDB1, EHMT2/G9a, RING1B/RNF2, KDM5s, e.g., KDM5A or KDM5D, HDACs, e.g., HDAC2 or HDAC5, EED, or SIRT5, e.g., SIRT5 or SIRT7; these factors are referred to herein as FXN Repressing Factors (FXN-RFs). The agents can include inhibitory nucleic acids and small molecule inhibitors.

*Small Molecule Inhibitors of FXN-RFs*

A number of small molecule inhibitors of FXN-RFs are known in the art, including those shown in Table 1, many of which are commercially available.

TABLE 1. SMALL MOLECULE INHIBITORS OF *FXN* REPRESSING FACTORS

| Gene Name                                                 | Symbol | Small Molecule Inhibitor                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------------------------------------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| enhancer of zeste 2 polycomb repressive complex 2 subunit | EZH2   | EPZ6438, GSK126, GSK343, DZNep, EI1, EPZ005678, UNC1999, 3-deazaneplanocin A hydrochloride, EPZ-6438 (tazemetostat)                                                                                                                                                                                                                                                                                                                                                                            |
| SET domain bifurcated 1                                   | SETDB1 | chaetocin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| euchromatic histone lysine methyltransferase 2            | EHMT2  | chaetocin, BIX-01294                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| lysine demethylase 5A                                     | KDM5A  | HDM inhibitor, 2,4-PDCA; JIB04; pyrazole derivative KDM5A inhibitors described in WO2015135094 (referred to herein as KDM5Ai), as well as compounds 65, 90-94, 4-Carboxy-2-heterocyclic pyridine derivatives (e.g., compounds 95-97), pyrazole derivatives (99-123), and others as described in McAllister et al., "Recent Progress in Histone Demethylase Inhibitors," J Med Chem. 2016 Feb 25;59(4):1308-29, as well as compounds described in WO2014164708, WO2014139326, and US20150065522 |
| DNA methyltransferase 3 alpha                             | DNMT3A | SGI-1027                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| DNA methyltransferase 3 beta                              | DNMT3B | SGI-1027                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| embryonic ectoderm development                            | EED    | EED226 (Qi et al., Nat Chem Biol. 2017 Jan 30); A395 (He et al., Nat Chem Biol. 2017 Jan 30)                                                                                                                                                                                                                                                                                                                                                                                                   |
| ring finger protein 2                                     | RNF2   | PRT4165                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| histone deacetylase 2                                     | HDAC2  | LMK235, PCI-24781, TSA, MC 1293, MGCD0103, 4SC-202, CI-994, TC-H 106, Santacruzamate A (CAY10683), mocentinostat (MGCD0103), sodium valproate, BG45                                                                                                                                                                                                                                                                                                                                            |
| histone deacetylase 5                                     | HDAC5  | LMK235, PCI-24781, TSA, MC1568, dacinostat, TMP269,                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| sirtuin 7                                                 | SIRT7  | 6-Chloro-2,3,4,9-tetrahydro-1 <i>H</i> -carbazole-1-carboxamide, sirtinol                                                                                                                                                                                                                                                                                                                                                                                                                      |

In some embodiments, the small molecule inhibitors of FXN-RF is not an HDAC inhibitor, or is not an inhibitor of HDAC1 or HDAC3, or is not RGFP109, is not compounds 106 (N1-(2-aminophenyl)-N7-p-tolylheptanediamide), 136 (N-(6-(2-amino-4-fluorophenylamino)-6-oxyhexyl)-4-methylbenzamide), or 109 (N-(6-(2-aminophenylamino)-6-oxyhexyl)-4-methylbenzamide) described in Rai et al., PLoS One. 2010; 5(1): e8825 and Sandi et al., Neurobiol Dis. 2011 Jun; 42(3): 496–505.

In addition, peptide-based inhibitors can be used, e.g., EZH2 inhibitor SAH-EZH2, which are hydrocarbon-stapled peptides that mimic the  $\alpha$ -helical EED binding domain of EZH2 (residues 40-68) to disrupt the protein interaction between EZH2 and EED). See, e.g., Kim et al., Nat Chem Biol. 2013 Oct;9(10):643-50. EZH2 is a component of a multi-subunit complex called Polycomb Repressor Complex 2 (PRC2). The other subunits of PRC2 are EED, SUZ12 and RbAp48. The finding that inhibition of EZH2 increases transcription of the TRE-FXN suggests that inhibition of other PRC2 subunits, in particular EED for which small molecule inhibitors are available, would have a similar effect.

#### *Inhibitory Nucleic Acids*

Inhibitory nucleic acids useful in the present methods and compositions include antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, single- or double-stranded RNA interference (RNAi) compounds such as siRNA compounds, modified bases/locked nucleic acids (LNAs), peptide nucleic acids (PNAs), and other oligomeric compounds or oligonucleotide mimetics that specifically hybridize to at least a portion of a target nucleic acid and modulate its function. In some embodiments, the inhibitory nucleic acids include antisense RNA, antisense DNA, chimeric antisense oligonucleotides, antisense oligonucleotides comprising modified linkages, interference RNA (RNAi), short interfering RNA (siRNA); a micro, interfering RNA (miRNA); a small, temporal RNA (stRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); small activating RNAs (saRNAs), or combinations thereof.

The following Table 2 provides exemplary target sequences for the FXN-RFs described herein:

TABLE 2. *FXN* REPRESSING FACTORS

| Gene Name                                                 | Symbol | NCBI RefSeq Acc. No. – Homo sapiens (nucleic acid)                                                                                                                   |
|-----------------------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DNA methyltransferase 3 alpha                             | DNMT3A | NM_022552.4 – isoform a<br>NM_153759.3 – isoform b<br>NM_001320892.1 – isoform c<br>NM_001320893.1 – isoform d                                                       |
| DNA methyltransferase 3 beta                              | DNMT3B | NM_006892.3 - isoform 1<br>NM_175848.1 – isoform 2<br>NM_175849.1 – isoform 3<br>NM_175850.2 – isoform 6<br>NM_001207055.1 – isoform 7<br>NM_001207056.1 – isoform 8 |
| embryonic ectoderm development                            | EED    | NM_003797.4 – isoform a<br>NM_001308007.1 – isoform c<br>NM_001330334.1 – isoform d                                                                                  |
| enhancer of zeste 2 polycomb repressive complex 2 subunit | EZH2   | NM_004456.4 – isoform a<br>NM_152998.2 – isoform b<br>NM_001203247.1 – isoform c<br>NM_001203248.1 – isoform d<br>NM_001203249.1 – isoform e                         |
| SET domain bifurcated 1                                   | SETDB1 | NM_001145415.1 – isoform 1<br>NM_012432.3 – isoform 2<br>NM_001243491.1 – isoform 3                                                                                  |
| euchromatic histone lysine methyltransferase 2            | EHMT2  | NM_006709.4 – isoform a<br>NM_025256.6 – isoform b<br>NM_001289413.1 – isoform c<br>NM_001318833.1 – isoform d                                                       |
| ring finger protein 2                                     | RNF2   | NM_007212.3                                                                                                                                                          |
| lysine demethylase 5A                                     | KDM5A  | NM_001042603.2                                                                                                                                                       |
| lysine demethylase 5D                                     | KDM5D  | NM_001146705.1 – isoform 1<br>NM_004653.4 – isoform 2<br>NM_001146706.1 – isoform 3                                                                                  |
| histone deacetylase 2                                     | HDAC2  | NM_001527.3                                                                                                                                                          |
| histone deacetylase 5                                     | HDAC5  | NM_005474.4 – isoform 1<br>NM_001015053.1 – isoform 3                                                                                                                |
| sirtuin 5                                                 | SIRT5  | NM_012241.4 – isoform 1<br>NM_031244.3 – isoform 2<br>NM_001193267.2 – isoform 3<br>NM_001242827.1 – isoform 4                                                       |
| sirtuin 7                                                 | SIRT7  | NM_016538.2                                                                                                                                                          |

In some embodiments, the inhibitory nucleic acids are 10 to 50, 10 to 20, 10 to 25, 13 to 50, or 13 to 30 nucleotides in length. One having ordinary skill in the art will appreciate that this embodies inhibitory nucleic acids having complementary portions of

5 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length, or

any range therewithin. In some embodiments, the inhibitory nucleic acids are 15 nucleotides in length. In some embodiments, the inhibitory nucleic acids are 12 or 13 to 20, 25, or 30 nucleotides in length. One having ordinary skill in the art will appreciate that this embodies inhibitory nucleic acids having complementary portions of 12, 13, 14,  
5 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length, or any range therewithin (complementary portions refers to those portions of the inhibitory nucleic acids that are complementary to the target sequence).

The inhibitory nucleic acids useful in the present methods are sufficiently complementary to the target RNA, i.e., hybridize sufficiently well and with sufficient  
10 specificity, to give the desired effect. "Complementary" refers to the capacity for pairing, through hydrogen bonding, between two sequences comprising naturally or non-naturally occurring bases or analogs thereof. For example, if a base at one position of an inhibitory nucleic acid is capable of hydrogen bonding with a base at the corresponding position of a RNA, then the bases are considered to be complementary to each other at that position.  
15 100% complementarity is not required.

Routine methods can be used to design an inhibitory nucleic acid that binds to the target sequence with sufficient specificity. In some embodiments, the methods include using bioinformatics methods known in the art to identify regions of secondary structure, e.g., one, two, or more stem-loop structures, or pseudoknots, and selecting those regions  
20 to target with an inhibitory nucleic acid. For example, "gene walk" methods can be used to optimize the inhibitory activity of the nucleic acid; for example, a series of oligonucleotides of 10-30 nucleotides spanning the length of a target RNA can be prepared, followed by testing for activity. Optionally, gaps, e.g., of 5-10 nucleotides or more, can be left between the target sequences to reduce the number of oligonucleotides  
25 synthesized and tested. GC content is preferably between about 30-60%. Contiguous runs of three or more Gs or Cs should be avoided where possible (for example, it may not be possible with very short (e.g., about 9-10 nt) oligonucleotides).

In some embodiments, the inhibitory nucleic acid molecules can be designed to target a specific region of the RNA sequence. For example, a specific functional region  
30 can be targeted, e.g., a region comprising a known RNA localization motif (i.e., a region complementary to the target nucleic acid on which the RNA acts). Alternatively or in addition, highly conserved regions can be targeted, e.g., regions identified by aligning sequences from disparate species such as primate (e.g., human) and rodent (e.g., mouse)

and looking for regions with high degrees of identity. Percent identity can be determined routinely using basic local alignment search tools (BLAST programs) (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656), e.g., using the default parameters.

5           Once one or more target regions, segments or sites have been identified, e.g., within a target sequence known in the art or provided herein, inhibitory nucleic acid compounds are chosen that are sufficiently complementary to the target, i.e., that hybridize sufficiently well and with sufficient specificity (i.e., do not substantially bind to other non-target RNAs), to give the desired effect.

10           In the context of this invention, hybridization means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. Complementary, as used herein, refers to the capacity for precise pairing between two  
15           nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a RNA molecule, then the inhibitory nucleic acid and the RNA are considered to be complementary to each other at that position. The inhibitory nucleic acids and the RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are  
20           occupied by nucleotides which can hydrogen bond with each other. Thus, “specifically hybridisable” and “complementary” are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the inhibitory nucleic acid and the RNA target. For example, if a base at one position of an inhibitory nucleic acid is capable of hydrogen bonding with a base at the  
25           corresponding position of a RNA, then the bases are considered to be complementary to each other at that position. 100% complementarity is not required.

          It is understood in the art that a complementary nucleic acid sequence need not be 100% complementary to that of its target nucleic acid to be specifically hybridisable. A complementary nucleic acid sequence for purposes of the present methods is specifically  
30           hybridisable when binding of the sequence to the target RNA molecule interferes with the normal function of the target RNA to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the sequence to non-target RNA sequences under conditions in which specific binding is desired, e.g., under

physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed under suitable conditions of stringency. For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and more preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and more preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30° C, more preferably of at least about 37° C, and most preferably of at least about 42° C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30° C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37° C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42° C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

For most applications, washing steps that follow hybridization will also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include a temperature of at least about 25° C, more preferably of at least about 42° C, and even more preferably of at least about 68° C. In a preferred embodiment, wash steps will occur at 25° C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42° C. in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 68° C in 15 mM NaCl, 1.5 mM trisodium

citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977);

Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al.

5 (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York.

In general, the inhibitory nucleic acids useful in the methods described herein  
10 have at least 80% sequence complementarity to a target region within the target nucleic acid, e.g., 90%, 95%, or 100% sequence complementarity to the target region within an RNA. For example, an antisense compound in which 18 of 20 nucleobases of the antisense oligonucleotide are complementary, and would therefore specifically hybridize, to a target region would represent 90 percent complementarity. Percent complementarity  
15 of an inhibitory nucleic acid with a region of a target nucleic acid can be determined routinely using basic local alignment search tools (BLAST programs) (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656). Inhibitory nucleic acids that hybridize to an RNA can be identified through routine experimentation. In general, the inhibitory nucleic acids must retain specificity for their  
20 target, i.e., must not directly bind to, or directly significantly affect expression levels of, transcripts other than the intended target.

For further disclosure regarding inhibitory nucleic acids, please see  
US2010/0317718 (antisense oligos); US2010/0249052 (double-stranded ribonucleic acid (dsRNA)); US2009/0181914 and US2010/0234451 (LNAs); US2007/0191294 (siRNA  
25 analogues); US2008/0249039 (modified siRNA); and WO2010/129746 and WO2010/040112 (inhibitory nucleic acids).

#### *Antisense*

In some embodiments, the inhibitory nucleic acids are antisense oligonucleotides. Antisense oligonucleotides are typically designed to block expression of a DNA or RNA  
30 target by binding to the target and halting expression at the level of transcription, translation, or splicing. Antisense oligonucleotides of the present invention are complementary nucleic acid sequences designed to hybridize under stringent conditions to an RNA. Thus, oligonucleotides are chosen that are sufficiently complementary to the

target, i.e., that hybridize sufficiently well and with sufficient specificity, to give the desired effect.

*siRNA/shRNA*

In some embodiments, the nucleic acid sequence that is complementary to a target  
 5 RNA can be an interfering RNA, including but not limited to a small interfering RNA  
 (“siRNA”) or a small hairpin RNA (“shRNA”). Methods for constructing interfering  
 RNAs are well known in the art. For example, the interfering RNA can be assembled  
 from two separate oligonucleotides, where one strand is the sense strand and the other is  
 the antisense strand, wherein the antisense and sense strands are self-complementary (i.e.,  
 10 each strand comprises nucleotide sequence that is complementary to nucleotide sequence  
 in the other strand; such as where the antisense strand and sense strand form a duplex or  
 double stranded structure); the antisense strand comprises nucleotide sequence that is  
 complementary to a nucleotide sequence in a target nucleic acid molecule or a portion  
 thereof (i.e., an undesired gene) and the sense strand comprises nucleotide sequence  
 15 corresponding to the target nucleic acid sequence or a portion thereof. Alternatively,  
 interfering RNA is assembled from a single oligonucleotide, where the self-  
 complementary sense and antisense regions are linked by means of nucleic acid based or  
 non-nucleic acid-based linker(s). The interfering RNA can be a polynucleotide with a  
 duplex, asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having  
 20 self-complementary sense and antisense regions, wherein the antisense region comprises  
 a nucleotide sequence that is complementary to nucleotide sequence in a separate target  
 nucleic acid molecule or a portion thereof and the sense region having nucleotide  
 sequence corresponding to the target nucleic acid sequence or a portion thereof. The  
 interfering can be a circular single-stranded polynucleotide having two or more loop  
 25 structures and a stem comprising self-complementary sense and antisense regions,  
 wherein the antisense region comprises nucleotide sequence that is complementary to  
 nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense  
 region having nucleotide sequence corresponding to the target nucleic acid sequence or a  
 portion thereof, and wherein the circular polynucleotide can be processed either in vivo or  
 30 in vitro to generate an active siRNA molecule capable of mediating RNA interference.

In some embodiments, the interfering RNA coding region encodes a self-  
 complementary RNA molecule having a sense region, an antisense region and a loop  
 region. Such an RNA molecule when expressed desirably forms a “hairpin” structure,

and is referred to herein as an “shRNA.” The loop region is generally between about 2 and about 10 nucleotides in length. In some embodiments, the loop region is from about 6 to about 9 nucleotides in length. In some embodiments, the sense region and the antisense region are between about 15 and about 20 nucleotides in length. Following post-transcriptional processing, the small hairpin RNA is converted into a siRNA by a cleavage event mediated by the enzyme Dicer, which is a member of the RNase III family. The siRNA is then capable of inhibiting the expression of a gene with which it shares homology. For details, see Brummelkamp et al., Science 296:550-553, (2002); Lee et al, Nature Biotechnol., 20, 500-505, (2002); Miyagishi and Taira, Nature Biotechnol 20:497-500, (2002); Paddison et al. Genes & Dev. 16:948-958, (2002); Paul, Nature Biotechnol, 20, 505-508, (2002); Sui, Proc. Natl. Acad. Sci. USA, 99(6), 5515-5520, (2002); Yu et al. Proc Natl Acad Sci USA 99:6047-6052, (2002).

The target RNA cleavage reaction guided by siRNAs is highly sequence specific. In general, siRNA containing a nucleotide sequences identical to a portion of the target nucleic acid are preferred for inhibition. However, 100% sequence identity between the siRNA and the target gene is not required to practice the present invention. Thus the invention has the advantage of being able to tolerate sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence. For example, siRNA sequences with insertions, deletions, and single point mutations relative to the target sequence have also been found to be effective for inhibition. Alternatively, siRNA sequences with nucleotide analog substitutions or insertions can be effective for inhibition. In general the siRNAs must retain specificity for their target, i.e., must not directly bind to, or directly significantly affect expression levels of, transcripts other than the intended target.

#### *Ribozymes*

Trans-cleaving enzymatic nucleic acid molecules can also be used; they have shown promise as therapeutic agents for human disease (Usman & McSwiggen, 1995 Ann. Rep. Med. Chem. 30, 285-294; Christoffersen and Marr, 1995 J. Med. Chem. 38, 2023-2037). Enzymatic nucleic acid molecules can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the RNA non- functional.

In general, enzymatic nucleic acids with RNA cleaving activity act by first binding to a target RNA. Such binding occurs through the target binding portion of a

enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

Several approaches such as in vitro selection (evolution) strategies (Orgel, 1979, Proc. R. Soc. London, B 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing a variety of reactions, such as cleavage and ligation of phosphodiester linkages and amide linkages, (Joyce, 1989, Gene, 82, 83-87; Beaudry et al., 1992, Science 257, 635-641; Joyce, 1992, Scientific American 267, 90-97; Breaker et al, 1994, TIBTECH 12, 268; Bartel et al, 1993, Science 261 :1411-1418; Szostak, 1993, TIBS 17, 89-93; Kumar et al, 1995, FASEB J., 9, 1183; Breaker, 1996, Curr. Op. Biotech., 1, 442). The development of ribozymes that are optimal for catalytic activity would contribute significantly to any strategy that employs RNA-cleaving ribozymes for the purpose of regulating gene expression. The hammerhead ribozyme, for example, functions with a catalytic rate (kcat) of about 1 min<sup>-1</sup> in the presence of saturating (10 mM) concentrations of Mg<sup>2+</sup> cofactor. An artificial "RNA ligase" ribozyme has been shown to catalyze the corresponding self-modification reaction with a rate of about 100 min<sup>-1</sup>. In addition, it is known that certain modified hammerhead ribozymes that have substrate binding arms made of DNA catalyze RNA cleavage with multiple turn-over rates that approach 100 min<sup>-1</sup>.

#### *Modified Inhibitory Nucleic Acids*

In some embodiments, the inhibitory nucleic acids used in the methods described herein are modified, e.g., comprise one or more modified bonds or bases. A number of modified bases include phosphorothioate, methylphosphonate, peptide nucleic acids, or locked nucleic acid (LNA) molecules. Some inhibitory nucleic acids are fully modified, while others are chimeric and contain two or more chemically distinct regions, each made up of at least one nucleotide. These inhibitory nucleic acids typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, for example, increased nuclease resistance, increased uptake into cells, increased binding affinity for the target) and a region that is a substrate for enzymes capable of cleaving

RNA:DNA or RNA:RNA hybrids. Chimeric inhibitory nucleic acids of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers.

5 Representative United States patents that teach the preparation of such hybrid structures comprise, but are not limited to, US patent nos. 5,013,830; 5,149,797; 5, 220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, each of which is herein incorporated by reference.

In some embodiments, the inhibitory nucleic acid comprises at least one  
 10 nucleotide modified at the 2' position of the sugar, most preferably a 2'-O-alkyl, 2'-O-alkyl-O-alkyl or 2'-fluoro-modified nucleotide. In other preferred embodiments, RNA modifications include 2'-fluoro, 2'-amino and 2' O-methyl modifications on the ribose of pyrimidines, abasic residues or an inverted base at the 3' end of the RNA. Such modifications are routinely incorporated into oligonucleotides and these oligonucleotides  
 15 have been shown to have a higher  $T_m$  (i.e., higher target binding affinity) than; 2'-deoxyoligonucleotides against a given target.

A number of nucleotide and nucleoside modifications have been shown to make the oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide; these modified oligos survive intact for a longer  
 20 time than unmodified oligonucleotides. Specific examples of modified oligonucleotides include those comprising modified backbones, for example, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are oligonucleotides with phosphorothioate backbones and those with heteroatom backbones,  
 25 particularly CH<sub>2</sub>-NH-O-CH<sub>2</sub>, CH<sub>2</sub>-N(CH<sub>3</sub>)-O-CH<sub>2</sub> (known as a methylene(methylimino) or MMI backbone], CH<sub>2</sub>-O-N(CH<sub>3</sub>)-CH<sub>2</sub>, CH<sub>2</sub>-N(CH<sub>3</sub>)-N(CH<sub>3</sub>)-CH<sub>2</sub> and O-N(CH<sub>3</sub>)-CH<sub>2</sub>-CH<sub>2</sub> backbones, wherein the native phosphodiester backbone is represented as O-P-O-CH<sub>2</sub>); amide backbones (see De Mesmaeker et al. Ace. Chem. Res. 1995, 28:366-374); morpholino backbone structures (see Summerton and Weller, U.S. Pat. No. 5,034,506); peptide nucleic acid (PNA) backbone (wherein the  
 30 phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone, see Nielsen et al., Science 1991, 254, 1497). Phosphorus-

containing linkages include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3'alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'; see US patent nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5, 177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455, 233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563, 253; 5,571,799; 5,587,361; and 5,625,050.

Morpholino-based oligomeric compounds are described in Dwaine A. Braasch and David R. Corey, *Biochemistry*, 2002, 41(14), 4503-4510; *Genesis*, volume 30, issue 3, 2001; Heasman, J., *Dev. Biol.*, 2002, 243, 209-214; Nasevicius et al., *Nat. Genet.*, 2000, 26, 216-220; Lacerra et al., *Proc. Natl. Acad. Sci.*, 2000, 97, 9591-9596; and U.S. Pat. No. 5,034,506, issued Jul. 23, 1991.

Cyclohexenyl nucleic acid oligonucleotide mimetics are described in Wang et al., *J. Am. Chem. Soc.*, 2000, 122, 8595-8602.

Modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts; see US patent nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264, 562; 5, 264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596, 086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623, 070;

5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.

One or more substituted sugar moieties can also be included, e.g., one of the following at the 2' position: OH, SH, SCH<sub>3</sub>, F, OCN, OCH<sub>3</sub>, OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub> CH<sub>3</sub>,  
 5 O(CH<sub>2</sub>)<sub>n</sub> NH<sub>2</sub> or O(CH<sub>2</sub>)<sub>n</sub> CH<sub>3</sub> where n is from 1 to about 10; C<sub>1</sub> to C<sub>10</sub> lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF<sub>3</sub>; OCF<sub>3</sub>; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH<sub>3</sub>; SO<sub>2</sub> CH<sub>3</sub>; ONO<sub>2</sub>; NO<sub>2</sub>; N<sub>3</sub>; NH<sub>2</sub>; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the  
 10 pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy [2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl)] (Martin et al, *Helv. Chim. Acta*, 1995, 78, 486). Other preferred modifications include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-propoxy (2'-OCH<sub>2</sub> CH<sub>2</sub>CH<sub>3</sub>)  
 15 and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group.

Inhibitory nucleic acids can also include, additionally or alternatively, nucleobase  
 20 (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2'  
 25 deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, as well as synthetic nucleobases, e.g., 2-aminoadenine, 2- (methylamino)adenine, 2-(imidazolylalkyl)adenine, 2- (aminoalkylamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5- hydroxymethyluracil, 8-azaguanine, 7-deazaguanine, N<sup>6</sup>  
 30 (6-aminohexyl)adenine and 2,6- diaminopurine. Kornberg, A., *DNA Replication*, W. H. Freeman & Co., San Francisco, 1980, pp75-77; Gebeyehu, G., et al. *Nucl. Acids Res.* 1987, 15:4513). A "universal" base known in the art, e.g., inosine, can also be included. 5-Me-C substitutions have been shown to increase nucleic acid duplex stability by 0.6-

1.2<0>C. (Sanghvi, Y. S., in Crooke, S. T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions.

It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide.

In some embodiments, both a sugar and an internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, for example, an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds comprise, but are not limited to, US patent nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al, *Science*, 1991, 254, 1497-1500.

Inhibitory nucleic acids can also include one or more nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases comprise other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8- thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5- bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylquanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3- deazaguanine and 3-deazaadenine.

Further, nucleobases comprise those disclosed in United States Patent No. 3,687,808, those disclosed in 'The Concise Encyclopedia of Polymer Science and Engineering', pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., 'Angewandte Chemie, International Edition', 1991, 30, page 613, and those disclosed by Sanghvi, Y. S., Chapter 15, 'Antisense Research and Applications', pages 289- 302, Crooke, S.T. and Lebleu, B. ea., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, comprising 2-aminopropyladenine, 5-propynyluracil and 5- propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds, 'Antisense Research and Applications', CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications. Modified nucleobases are described in US patent nos. 3,687,808, as well as 4,845,205; 5,130,302; 5,134,066; 5,175, 273; 5, 367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,596,091; 5,614,617; 5,750,692, and 5,681,941, each of which is herein incorporated by reference.

In some embodiments, the inhibitory nucleic acids are chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide. Such moieties comprise but are not limited to, lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S- tritylthiol (Manoharan et al, Ann. N. Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Lett., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49- 54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1 ,2-di-O-hexadecyl- rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Mancharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim.

Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-t  
oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937). See  
also US patent nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730;  
5,552, 538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802;  
5,138,045; 5,414,077; 5,486, 603; 5,512,439; 5,578,718; 5,608,046; 4,587,044;  
4,605,735; 4,667,025; 4,762, 779; 4,789,737; 4,824,941; 4,835,263; 4,876,335;  
4,904,582; 4,958,013; 5,082, 830; 5,112,963; 5,214,136; 5,082,830; 5,112,963;  
5,214,136; 5, 245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873;  
5,317,098; 5,371,241; 5,391, 723; 5,416,203; 5,451,463; 5,510,475; 5,512,667;  
5,514,785; 5, 565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726;  
5,597,696; 5,599,923; 5,599, 928 and 5,688,941, each of which is herein incorporated by  
reference.

These moieties or conjugates can include conjugate groups covalently bound to  
functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the  
invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene  
glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers,  
and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate  
groups include cholesterol, lipids, phospholipids, biotin, phenazine, folate,  
phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes.

Groups that enhance the pharmacodynamic properties, in the context of this invention,  
include groups that improve uptake, enhance resistance to degradation, and/or strengthen  
sequence-specific hybridization with the target nucleic acid. Groups that enhance the  
pharmacokinetic properties, in the context of this invention, include groups that improve  
uptake, distribution, metabolism or excretion of the compounds of the present invention.

Representative conjugate groups are disclosed in International Patent Application No.  
PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. No. 6,287,860, which are  
incorporated herein by reference. Conjugate moieties include, but are not limited to, lipid  
moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-5-tritylthiol, a  
thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid,  
e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-  
phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a  
palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxy cholesterol moiety.  
See, e.g., U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313;

5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802;  
 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735;  
 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013;  
 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469;  
 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203;  
 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481;  
 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941.

#### *Locked Nucleic Acids (LNAs)*

In some embodiments, the modified inhibitory nucleic acids used in the methods  
 10 described herein comprise locked nucleic acid (LNA) molecules, e.g., including [alpha]-  
 L-LNAs. LNAs comprise ribonucleic acid analogues wherein the ribose ring is “locked”  
 by a methylene bridge between the 2'-oxygen and the 4'-carbon – i.e., oligonucleotides  
 containing at least one LNA monomer, that is, one 2'-O,4'-C-methylene-β-D-ribofuranosyl  
 nucleotide. LNA bases form standard Watson-Crick base pairs but the locked  
 15 configuration increases the rate and stability of the basepairing reaction (Jepsen et al.,  
*Oligonucleotides*, 14, 130-146 (2004)). LNAs also have increased affinity to base pair  
 with RNA as compared to DNA. These properties render LNAs especially useful as  
 probes for fluorescence in situ hybridization (FISH) and comparative genomic  
 hybridization, as knockdown tools for miRNAs, and as antisense oligonucleotides to  
 20 target mRNAs or other RNAs, e.g., RNAs as described herien.

The LNA molecules can include molecules comprising 10-30, e.g., 12-24, e.g., 12,  
 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in each  
 strand, wherein one of the strands is substantially identical, e.g., at least 80% (or more,  
 e.g., 85%, 90%, 95%, or 100%) identical, e.g., having 3, 2, 1, or 0 mismatched  
 25 nucleotide(s), to a target region in the RNA. The LNA molecules can be chemically  
 synthesized using methods known in the art.

The LNA molecules can be designed using any method known in the art; a  
 number of algorithms are known, and are commercially available (e.g., on the internet, for  
 example at [exiqon.com](http://exiqon.com)). See, e.g., You et al., *Nuc. Acids. Res.* 34:e60 (2006); McTigue  
 30 et al., *Biochemistry* 43:5388-405 (2004); and Levin et al., *Nuc. Acids. Res.* 34:e142  
 (2006). For example, “gene walk” methods, similar to those used to design antisense  
 oligos, can be used to optimize the inhibitory activity of the LNA; for example, a series of  
 oligonucleotides of 10-30 nucleotides spanning the length of a target RNA can be

prepared, followed by testing for activity. Optionally, gaps, e.g., of 5-10 nucleotides or more, can be left between the LNAs to reduce the number of oligonucleotides synthesized and tested. GC content is preferably between about 30-60%. General guidelines for designing LNAs are known in the art; for example, LNA sequences will bind very tightly to other LNA sequences, so it is preferable to avoid significant complementarity within an LNA. Contiguous runs of more than four LNA residues, should be avoided where possible (for example, it may not be possible with very short (e.g., about 9-10 nt) oligonucleotides). In some embodiments, the LNAs are xylo-LNAs.

For additional information regarding LNAs see U.S. Pat. Nos. 6,268,490; 6,734,291; 6,770,748; 6,794,499; 7,034,133; 7,053,207; 7,060,809; 7,084,125; and 7,572,582; and U.S. Pre-Grant Pub. Nos. 20100267018; 20100261175; and 20100035968; Koshkin et al. Tetrahedron 54, 3607-3630 (1998); Obika et al. Tetrahedron Lett. 39, 5401-5404 (1998); Jepsen et al., Oligonucleotides 14:130-146 (2004); Kauppinen et al., Drug Disc. Today 2(3):287-290 (2005); and Ponting et al., Cell 136(4):629-641 (2009), and references cited therein.

#### *Making and Using Inhibitory Nucleic Acids*

The nucleic acid sequences used to practice the methods described herein, whether RNA, cDNA, genomic DNA, vectors, viruses or hybrids thereof, can be isolated from a variety of sources, genetically engineered, amplified, and/or expressed/ generated recombinantly. Recombinant nucleic acid sequences can be individually isolated or cloned and tested for a desired activity. Any recombinant expression system can be used, including e.g. in vitro, bacterial, fungal, mammalian, yeast, insect or plant cell expression systems.

Nucleic acid sequences of the invention can be inserted into delivery vectors and expressed from transcription units within the vectors. The recombinant vectors can be DNA plasmids or viral vectors. Generation of the vector construct can be accomplished using any suitable genetic engineering techniques well known in the art, including, without limitation, the standard techniques of PCR, oligonucleotide synthesis, restriction endonuclease digestion, ligation, transformation, plasmid purification, and DNA sequencing, for example as described in Sambrook et al. Molecular Cloning: A Laboratory Manual. (1989)), Coffin et al. (Retroviruses. (1997)) and "RNA Viruses: A Practical Approach" (Alan J. Cann, Ed., Oxford University Press, (2000)). As will be apparent to one of ordinary skill in the art, a variety of suitable vectors are available for

transferring nucleic acids of the invention into cells. The selection of an appropriate vector to deliver nucleic acids and optimization of the conditions for insertion of the selected expression vector into the cell, are within the scope of one of ordinary skill in the art without the need for undue experimentation. Viral vectors comprise a nucleotide  
5 sequence having sequences for the production of recombinant virus in a packaging cell. Viral vectors expressing nucleic acids of the invention can be constructed based on viral backbones including, but not limited to, a retrovirus, lentivirus, adenovirus, adeno-associated virus, pox virus or alphavirus. The recombinant vectors capable of expressing the nucleic acids of the invention can be delivered as described herein, and persist in  
10 target cells (e.g., stable transformants).

Nucleic acid sequences used to practice this invention can be synthesized in vitro by well-known chemical synthesis techniques, as described in, e.g., Adams (1983) *J. Am. Chem. Soc.* 105:661; Belousov (1997) *Nucleic Acids Res.* 25:3440-3444; Frenkel (1995) *Free Radic. Biol. Med.* 19:373-380; Blommers (1994) *Biochemistry* 33:7886-7896;  
15 Narang (1979) *Meth. Enzymol.* 68:90; Brown (1979) *Meth. Enzymol.* 68:109; Beaucage (1981) *Tetra. Lett.* 22:1859; U.S. Patent No. 4,458,066.

Nucleic acid sequences of the invention can be stabilized against nucleolytic degradation such as by the incorporation of a modification, e.g., a nucleotide modification. For example, nucleic acid sequences of the invention includes a  
20 phosphorothioate at least the first, second, or third internucleotide linkage at the 5' or 3' end of the nucleotide sequence. As another example, the nucleic acid sequence can include a 2'-modified nucleotide, e.g., a 2'-deoxy, 2'-deoxy-2'-fluoro, 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE), 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), 2'-O-dimethylaminoethoxyethyl  
25 (2'-O-DMAEOE), or 2'-O--N-methylacetamido (2'-O--NMA). As another example, the nucleic acid sequence can include at least one 2'-O-methyl-modified nucleotide, and in some embodiments, all of the nucleotides include a 2'-O-methyl modification. In some embodiments, the nucleic acids are "locked," i.e., comprise nucleic acid analogues in which the ribose ring is "locked" by a methylene bridge connecting the 2'-O atom and the  
30 4'-C atom (see, e.g., Kaupinnen et al., *Drug Disc. Today* 2(3):287-290 (2005); Koshkin et al., *J. Am. Chem. Soc.*, 120(50):13252-13253 (1998)). For additional modifications see US 20100004320, US 20090298916, and US 20090143326.

Techniques for the manipulation of nucleic acids used to practice this invention, such as, e.g., subcloning, labeling probes (e.g., random-primer labeling using Klenow polymerase, nick translation, amplification), sequencing, hybridization and the like are well described in the scientific and patent literature, see, e.g., Sambrook et al., *Molecular Cloning; A Laboratory Manual* 3d ed. (2001); *Current Protocols in Molecular Biology*, Ausubel et al., eds. (John Wiley & Sons, Inc., New York 2010); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); *Laboratory Techniques In Biochemistry And Molecular Biology: Hybridization With Nucleic Acid Probes, Part I. Theory and Nucleic Acid Preparation*, Tijssen, ed. Elsevier, N.Y. (1993).

#### *Pharmaceutical Compositions*

The methods described herein can include the administration of pharmaceutical compositions and formulations comprising inhibitory nucleic acid sequences designed to target an RNA.

In some embodiments, the compositions are formulated with a pharmaceutically acceptable carrier. The pharmaceutical compositions and formulations can be administered parenterally, topically, orally or by local administration, such as by aerosol or transdermally. The pharmaceutical compositions can be formulated in any way and can be administered in a variety of unit dosage forms depending upon the condition or disease and the degree of illness, the general medical condition of each patient, the resulting preferred method of administration and the like. Details on techniques for formulation and administration of pharmaceuticals are well described in the scientific and patent literature, see, e.g., *Remington: The Science and Practice of Pharmacy*, 21st ed., 2005.

The inhibitory nucleic acids can be administered alone or as a component of a pharmaceutical formulation (composition). The compounds may be formulated for administration, in any convenient way for use in human or veterinary medicine. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

Formulations of the compositions of the invention include those suitable for intradermal, inhalation, oral/ nasal, topical, parenteral, rectal, and/or intravaginal administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of

active ingredient (e.g., nucleic acid sequences of this invention) which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration, e.g., intradermal or inhalation. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect, e.g., an antigen specific T cell or humoral response.

Pharmaceutical formulations can be prepared according to any method known to the art for the manufacture of pharmaceuticals. Such drugs can contain sweetening agents, flavoring agents, coloring agents and preserving agents. A formulation can be admixed with nontoxic pharmaceutically acceptable excipients which are suitable for manufacture. Formulations may comprise one or more diluents, emulsifiers, preservatives, buffers, excipients, etc. and may be provided in such forms as liquids, powders, emulsions, lyophilized powders, sprays, creams, lotions, controlled release formulations, tablets, pills, gels, on patches, in implants, etc.

Pharmaceutical formulations for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in appropriate and suitable dosages. Such carriers enable the pharmaceuticals to be formulated in unit dosage forms as tablets, pills, powder, dragees, capsules, liquids, lozenges, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient. Pharmaceutical preparations for oral use can be formulated as a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable additional compounds, if desired, to obtain tablets or dragee cores. Suitable solid excipients are carbohydrate or protein fillers include, e.g., sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxy-methylcellulose; and gums including arabic and tragacanth; and proteins, e.g., gelatin and collagen. Disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate. Push-fit capsules can contain active agents mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active agents can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

Aqueous suspensions can contain an active agent (e.g., nucleic acid sequences of the invention) in admixture with excipients suitable for the manufacture of aqueous suspensions, e.g., for aqueous intradermal injections. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a condensation product of ethylene oxide with a partial ester derived from fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan mono-oleate). The aqueous suspension can also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin. Formulations can be adjusted for osmolarity.

In some embodiments, oil-based pharmaceuticals are used for administration of nucleic acid sequences of the invention. Oil-based suspensions can be formulated by suspending an active agent in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin; or a mixture of these. See e.g., U.S. Patent No. 5,716,928 describing using essential oils or essential oil components for increasing bioavailability and reducing inter- and intra-individual variability of orally administered hydrophobic pharmaceutical compounds (see also U.S. Patent No. 5,858,401). The oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents can be added to provide a palatable oral preparation, such as glycerol, sorbitol or sucrose. These formulations can be preserved by the addition of an antioxidant such as ascorbic acid. As an example of an injectable oil vehicle, see Minto (1997) J. Pharmacol. Exp. Ther. 281:93-102.

Pharmaceutical formulations can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil, described above, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-

oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsion can also contain sweetening agents and flavoring agents, as in the formulation of syrups and elixirs. Such formulations can also contain a demulcent, a preservative, or a coloring agent. In alternative embodiments, these injectable oil-in-water emulsions of the invention comprise a paraffin oil, a sorbitan monooleate, an ethoxylated sorbitan monooleate and/or an ethoxylated sorbitan trioleate.

The pharmaceutical compounds can also be administered by in intranasal, intraocular and intravaginal routes including suppositories, insufflation, powders and aerosol formulations (for examples of steroid inhalants, see e.g., Rohatagi (1995) *J. Clin. Pharmacol.* 35:1187-1193; Tjwa (1995) *Ann. Allergy Asthma Immunol.* 75:107-111). Suppositories formulations can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at body temperatures and will therefore melt in the body to release the drug. Such materials are cocoa butter and polyethylene glycols.

In some embodiments, the pharmaceutical compounds can be delivered transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.

In some embodiments, the pharmaceutical compounds can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug which slowly release subcutaneously; see Rao (1995) *J. Biomater Sci. Polym. Ed.* 7:623-645; as biodegradable and injectable gel formulations, see, e.g., Gao (1995) *Pharm. Res.* 12:857-863 (1995); or, as microspheres for oral administration, see, e.g., Eyles (1997) *J. Pharm. Pharmacol.* 49:669-674.

In some embodiments, the pharmaceutical compounds can be parenterally administered, such as by intravenous (IV) administration or administration into a body cavity or lumen of an organ. These formulations can comprise a solution of active agent dissolved in a pharmaceutically acceptable carrier. Acceptable vehicles and solvents that can be employed are water and Ringer's solution, an isotonic sodium chloride. In addition, sterile fixed oils can be employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can likewise be used in the preparation of injectables. These solutions are sterile and generally free of undesirable matter. These formulations may be sterilized by conventional, well known sterilization techniques. The

formulations may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these  
5 formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like, in accordance with the particular mode of administration selected and the patient's needs. For IV administration, the formulation can be a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated using those suitable dispersing or wetting  
10 agents and suspending agents. The sterile injectable preparation can also be a suspension in a nontoxic parenterally-acceptable diluent or solvent, such as a solution of 1,3-butanediol. The administration can be by bolus or continuous infusion (e.g., substantially uninterrupted introduction into a blood vessel for a specified period of time).

In some embodiments, the pharmaceutical compounds and formulations can be  
15 lyophilized. Stable lyophilized formulations comprising an inhibitory nucleic acid can be made by lyophilizing a solution comprising a pharmaceutical of the invention and a bulking agent, e.g., mannitol, trehalose, raffinose, and sucrose or mixtures thereof. A process for preparing a stable lyophilized formulation can include lyophilizing a solution about 2.5 mg/mL protein, about 15 mg/mL sucrose, about 19 mg/mL NaCl, and a sodium  
20 citrate buffer having a pH greater than 5.5 but less than 6.5. See, e.g., U.S. 20040028670.

The compositions and formulations can be delivered by the use of liposomes. By using liposomes, particularly where the liposome surface carries ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the active agent into target cells *in vivo*. See, e.g., U.S. Patent Nos. 6,063,400;  
25 6,007,839; Al-Muhammed (1996) J. Microencapsul. 13:293-306; Chonn (1995) Curr. Opin. Biotechnol. 6:698-708; Ostro (1989) Am. J. Hosp. Pharm. 46:1576-1587. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles that have a membrane formed from a lipophilic material and an aqueous interior  
30 that contains the composition to be delivered. Cationic liposomes are positively charged liposomes that are believed to interact with negatively charged DNA molecules to form a stable complex. Liposomes that are pH-sensitive or negatively-charged are believed to

entrap DNA rather than complex with it. Both cationic and noncationic liposomes have been used to deliver DNA to cells.

Liposomes can also include "sterically stabilized" liposomes, i.e., liposomes comprising one or more specialized lipids. When incorporated into liposomes, these specialized lipids result in liposomes with enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. Liposomes and their uses are further described in U.S. Pat. No. 6,287,860.

The formulations of the invention can be administered for prophylactic and/or therapeutic treatments. In some embodiments, for therapeutic applications, compositions are administered to a subject who is in need of reduced triglyceride levels, or who is at risk of or has a disorder described herein, in an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of the disorder or its complications; this can be called a therapeutically effective amount. For example, in some embodiments, pharmaceutical compositions of the invention are administered in an amount sufficient to decrease serum levels of triglycerides in the subject.

The amount of pharmaceutical composition adequate to accomplish this is a therapeutically effective dose. The dosage schedule and amounts effective for this use, i.e., the dosing regimen, will depend upon a variety of factors, including the stage of the disease or condition, the severity of the disease or condition, the general state of the patient's health, the patient's physical status, age and the like. In calculating the dosage regimen for a patient, the mode of administration also is taken into consideration.

The dosage regimen also takes into consideration pharmacokinetics parameters well known in the art, i.e., the active agents' rate of absorption, bioavailability, metabolism, clearance, and the like (see, e.g., Hidalgo-Aragones (1996) *J. Steroid Biochem. Mol. Biol.* 58:611-617; Groning (1996) *Pharmazie* 51:337-341; Fotherby (1996) *Contraception* 54:59-69; Johnson (1995) *J. Pharm. Sci.* 84:1144-1146; Rohatagi (1995) *Pharmazie* 50:610-613; Brophy (1983) *Eur. J. Clin. Pharmacol.* 24:103-108; *Remington: The Science and Practice of Pharmacy*, 21st ed., 2005). The state of the art allows the clinician to determine the dosage regimen for each individual patient, active agent and disease or condition treated. Guidelines provided for similar compositions used

as pharmaceuticals can be used as guidance to determine the dosage regiment, i.e., dose schedule and dosage levels, administered practicing the methods of the invention are correct and appropriate.

5 Single or multiple administrations of formulations can be given depending on for example: the dosage and frequency as required and tolerated by the patient, the degree and amount of therapeutic effect generated after each administration (e.g., effect on tumor size or growth), and the like. The formulations should provide a sufficient quantity of active agent to effectively treat, prevent or ameliorate conditions, diseases or symptoms.

10 In alternative embodiments, pharmaceutical formulations for oral administration are in a daily amount of between about 1 to 100 or more mg per kilogram of body weight per day. Lower dosages can be used, in contrast to administration orally, into the blood stream, into a body cavity or into a lumen of an organ. Substantially higher dosages can be used in topical or oral administration or administering by powders, spray or inhalation. Actual methods for preparing parenterally or non-parenterally administrable formulations  
15 will be known or apparent to those skilled in the art and are described in more detail in such publications as *Remington: The Science and Practice of Pharmacy*, 21st ed., 2005.

Various studies have reported successful mammalian dosing using complementary nucleic acid sequences. For example, Esau C., et al., (2006) *Cell Metabolism*, 3(2):87-98 reported dosing of normal mice with intraperitoneal doses of miR-122 antisense  
20 oligonucleotide ranging from 12.5 to 75 mg/kg twice weekly for 4 weeks. The mice appeared healthy and normal at the end of treatment, with no loss of body weight or reduced food intake. Plasma transaminase levels were in the normal range (AST  $\frac{3}{4}$  45, ALT  $\frac{3}{4}$  35) for all doses with the exception of the 75 mg/kg dose of miR-122 ASO, which showed a very mild increase in ALT and AST levels. They concluded that 50mg/kg was  
25 an effective, non-toxic dose. Another study by Krützfeldt J., et al., (2005) *Nature* 438, 685-689, injected anatgomirs to silence miR-122 in mice using a total dose of 80, 160 or 240 mg per kg body weight. The highest dose resulted in a complete loss of miR-122 signal. In yet another study, locked nucleic acids ("LNAs") were successfully applied in primates to silence miR-122. Elmen J., et al., (2008) *Nature* 452, 896-899, report that  
30 efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg-1 LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals.

In some embodiments, the methods described herein can include co-administration with other drugs or pharmaceuticals, e.g., compositions for providing cholesterol homeostasis. For example, the inhibitory nucleic acids can be co-administered with drugs for treating or reducing risk of a disorder described herein.

5           Delivery of siRNA *in vivo*

The overall efficacy of RNAi-based therapies depends on the efficiency of the delivery system to selectively target infected or diseased tissue versus normal non-malignant tissue, and on the stability of the agent within the cell. However, since 1998 when the first human RNAi-based clinical trials occurred, the number of clinical trials  
10       involving RNAi therapies targeting the liver has rapidly increased (Sehgal, A et al (2013) J. Hepatology 59: 1354-1359). To avoid rapid degradation of unmodified siRNAs in the blood and serum *in vivo*, chemical modification or conjugate formation (simple or poly-) may be used by those skilled in the art. Examples of modifications may include lipid carriers, such as liposomal vehicles (Kanasty, R et al (2013) Nature Mater. 12, 967-977);  
15       Watanabe et al (2007) J. Hepatol 47:744-50; Aleku et al (2008) Cancer Res 68:9788-98; Moreira et al (2008) J. Nanosci Nanotechnol 8:2187-204; cationic carriers, such as cyclodextrin-based cationic polymers (Heidel et al (2007) Clin Cancer Res 13:2207-15) and biodegradable components (Dimitrova et al (2008). In some embodiments, liposome particles (Morrissey, DV et al (2005) Biotechnol 23:1002-1007), PEGylated nanoparticles  
20       (Carmona, S et al (2009) Mol Pharm 6:706-717), or Dynamic PolyConjugate (DPC) (Rozema et al (2007) PNAS 104: 12982-12987) may be used to deliver siRNAs to the liver. In some embodiments, this delivery system may feature reversibly masked polymers that are only revealed under specific conditions, such as the acidic environment of the endosome (Rozema et al (2007) PNAS 104: 12982-12987). In some embodiments,  
25       the delivery system may dependent on the attachment to a liver-specific receptor on the cell surface of hepatocytes, such asialoglycoprotein (Wu, J et al (2002) Front Biosci 7:d717-d725). In some embodiments, the target siRNA may directly be conjugated to cholesterol (Wooddell, C et al (2013) Mol Therapy 21:973-985). In some embodiments hydrodynamic intravenous injections and electrical pulsing may be used to directly  
30       deliver RNAi therapeutics (Morrissey et al (2005) Hepatology 41:1349-56; Golzio et al (2005) Gen Ther 12:246-51). RNAi therapeutics may also be delivered via electroporation of purified exosomes (Alvarez-Erviti et al (2011) Nat Biotechnol 29:341-

345). For more information on *in vivo* delivery of RNAi, please see US 12/479,747; US 8,501,930, US 8,017,804; US 8,357,722; US 8,314,227; and US 7,371,404.

### **Pharmaceutical Compositions and Methods of Administration**

The methods described herein include the use of pharmaceutical compositions  
5 comprising an inhibitor of a FXN Repressing Factor (FXN-RF) as an active ingredient.

Pharmaceutical compositions typically include a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical  
10 administration.

Pharmaceutical compositions are typically formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.

15 Methods of formulating suitable pharmaceutical compositions are known in the art, see, e.g., *Remington: The Science and Practice of Pharmacy*, 21st ed., 2005; and the books in the series *Drugs and the Pharmaceutical Sciences: A Series of Textbooks and Monographs* (Dekker, NY). For example, solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile  
20 diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or  
25 dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the  
30 extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy

syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a

sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds can be delivered in the form of an aerosol spray from a pressured container or dispenser that contains a suitable  
5 propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Such methods include those described in U.S. Patent No. 6,468,798.

Systemic administration of a therapeutic compound as described herein can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the  
10 formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

15 The pharmaceutical compositions can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

Therapeutic compounds that are or include nucleic acids can be administered by any method suitable for administration of nucleic acid agents, such as a DNA vaccine.  
20 These methods include gene guns, bio injectors, and skin patches as well as needle-free methods such as the micro-particle DNA vaccine technology disclosed in U.S. Patent No. 6,194,389, and the mammalian transdermal needle-free vaccination with powder-form vaccine as disclosed in U.S. Patent No. 6,168,587. Additionally, intranasal delivery is possible, as described in, *inter alia*, Hamajima et al., Clin. Immunol. Immunopathol.,  
25 88(2), 205-10 (1998). Liposomes (e.g., as described in U.S. Patent No. 6,472,375) and microencapsulation can also be used. Biodegradable targetable microparticle delivery systems can also be used (e.g., as described in U.S. Patent No. 6,471,996).

In one embodiment, the therapeutic compounds are prepared with carriers that will protect the therapeutic compounds against rapid elimination from the body, such as a  
30 controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Such formulations can be prepared using standard techniques, or obtained commercially,

e.g., from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to selected cells with monoclonal antibodies to cellular antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S.

5 Patent No. 4,522,811.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

### **Dosage**

10 An “effective amount” is an amount sufficient to effect beneficial or desired results. For example, a therapeutic amount is one that achieves the desired therapeutic effect. This amount can be the same or different from a prophylactically effective amount, which is an amount necessary to prevent onset of disease or disease symptoms. An effective amount can be administered in one or more administrations, applications or dosages. A therapeutically effective amount of a therapeutic compound (i.e., an effective  
15 dosage) depends on the therapeutic compounds selected. The compositions can be administered one from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general  
20 health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of the therapeutic compounds described herein can include a single treatment or a series of treatments.

Dosage, toxicity and therapeutic efficacy of the therapeutic compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental  
25 animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to  
30 design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies

preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC<sub>50</sub> (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

### EXAMPLES

The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

#### Example 1. Identification of Targets for De-Repressing TRE-*FXN*

##### Expression in FA iPSCs

Factors responsible for depositing repressive marks or for removing activating marks are potential targets to increase transcription of the epigenetically repressed TRE-*FXN* gene. The following table is a non-comprehensive list of factors responsible for depositing or removing the epigenetic marks on the repressed TRE-*FXN* gene.

**Table 3 - factors potentially responsible for depositing or removing the epigenetic marks on the repressed TRE-*FXN* gene**

| Epigenetic mark | Potential target(s)                   |
|-----------------|---------------------------------------|
| DNAmc           | DNMT1, DNMT3A, DNMT3B                 |
| H3K27me3        | EZH2                                  |
| H3K9me3         | SETDB1, EHMT1/GLP, EHMT2/G9a, SUV39H1 |
| H4K20me3        | SUV420H1, SUV420H2                    |
| H2Aub           | RING1B/RNF2                           |
| H2A/2B/3/4ac    | HDAC1-11, SIRT1-7                     |
| H3K4me3         | KDM5A-D                               |

To identify epigenetic regulators that mediate repression of TRE-*FXN*, we assembled a small-scale shRNA library comprising 162 shRNAs directed against 33 well-characterized epigenetic regulators known to mediate transcriptional repression, including those listed in Table 3. Each shRNA was packaged into lentivirus particles and transduced into undifferentiated induced pluripotent stem cells (iPSCs) derived from fibroblasts from an FA patient (Ku et al. 2010, *Cell Stem Cell* 7:631-637), i.e., the FA

iPSC line GM23404 (obtained from the Coriell Institute for Medical Research) derived from an FA patient, GM03816, who has alleles of ~330 and 380 GAA-TTC repeats and exhibits spinal-cerebral degeneration and cardiomyopathy. These FA iPSCs harbor a repressed TRE-*FXN* gene, and therefore serve as a useful model system for studying disease mechanisms and for drug screening approaches. Twenty days post-transfection, mRNA was prepared and *FXN* expression analyzed by quantitative RT-PCR (qRT-PCR). A candidate was considered to be positive if at least two unrelated shRNAs directed against the same target resulted in: (1) a statistically significant increase in *FXN* transcription compared to that obtained with a control non-silencing (NS) shRNA, and (2) decreased mRNA levels of the target gene. A representative subset of the results obtained in the complete screen of the 162 shRNAs is shown in Figure 1A, which enabled us to identify 10 epigenetic repressors of the TRE-*FXN* gene: DNMT3A, DNMT3B, EZH2, SETDB1, EHMT2/G9a, RING1B/RNF2, KDM5A, HDAC2, HDAC5, and SIRT7 (Table 4). For convenience we refer to these factors as *FXN* Repressing Factors (*FXN*-RFs). The immunoblot results of Figure 1B show that knockdown of each *FXN*-RF also increased frataxin protein to levels comparable to that observed in an iPSC line derived from a normal individual (BJ1-iPS4 cells (Sheridan et al., PLoS One 6(10): e26203); hereafter called normal iPSCs).

Table 4 - List of 10 *FXN*-RFs and their epigenetic roles

| <b>FXN-RF</b> | <b>Role</b>                    |
|---------------|--------------------------------|
| DNMT3A        | DNA methyltransferase          |
| DNMT3B        | DNA methyltransferase          |
| EZH2          | PRC2 (H2K27 methyltransferase) |
| SETDB1        | H3K9 methyltransferase         |
| EHMT2/G9a     | H3K9 methyltransferase         |
| RING1B/RNF2   | PRC1 (H2A ubiquitin ligase)    |
| KDM5A         | H3K4 demethylase               |
| HDAC2         | Histone deacetylase            |
| HDAC5         | Histone deacetylase            |
| SIRT7         | Sirtuin                        |

To confirm these results, an isogenic pair of FA iPSC lines was obtained (from Marek Napierala, University of Alabama School of Medicine) in which the GAA•TTC repeat is either intact (GAA-intact) or has been deleted on one allele (GAA-excised) (Li et al. 2015, *Mol Ther* 23:1055). The cell lines were derived from an FA patient, FRDA68, who has alleles of ~1400 and 560 GAA•TTC repeats; the GAA-excised derivative contains only the allele with 560 repeats. This pair of isogenic FA cell lines is a powerful

experimental tool that recapitulates the difference in *FXN* transcription between asymptomatic carriers and FA patients and controls for individual differences in gene expression. Figure 1C shows that knockdown of each FXN-RF in FA(GAA-intact) iPSCs upregulated TRE-*FXN* transcription to levels comparable to that observed in FA(GAA-excised) iPSCs.

Epigenetic regulators are typically associated with the promoters and/or genes upon which they act. To determine whether the 10 FXN-RFs are associated with the TRE-*FXN* gene chromatin immunoprecipitation (ChIP) experiments were performed. Figure 1D shows that in FA(GM23404) iPSCs all 10 FXN-RFs are enriched within the first intron of the TRE-*FXN* gene, which is the site of the GAA•TTC repeats, and, as expected, not on the first intron of the *FXN* gene in normal iPSCs or on a representative transcriptionally active control promoter (*APRT*). Furthermore, SUV39H1 or DNMT1, which are not involved in repression of TRE-*FXN* (see Figure 1A), were not enriched on the first intron of the TRE-*FXN* gene.

As previously shown, factors involved in epigenetic silencing of a tumor suppressor gene in cancer cells are recruited to the promoter in an ordered pathway resulting from sequential recruitment by other, previously-bound epigenetic regulators (Wajapeyee et al., (2013) *Genes Dev* 27(20): 2221-6). This conclusion was based on RNAi-based epistasis analysis, in which each epigenetic repressor is systematically knocked down and the effect on binding of all epigenetic repressors is determined in a ChIP assay. To determine if epigenetic repression of TRE-*FXN* occurs through a similar mechanism of ordered FXN-RF recruitment, RNAi-based epistasis analysis was performed for the 10 FXN-RFs. Figures 1E-F shows that binding of EZH2 did not require any of the other FXN-RFs, allowing us to place it first in the recruitment pathway. By contrast, binding of DNMT3A (Figures 1E-F) and DNMT3B were dependent upon all of the FXN-RFs, allowing them to be placed last in the pathway. The other seven FXN-RFs analyzed showed a dependence on other FXN-RFs that was intermediate to that of EZH2 and DNMT3A/3B (due to space limitations only a representative intermediary FXN-RF, KDM5A, is shown in Figures 1E-F). Collectively, this epistasis analysis enabled us to construct an ordered pathway of FXN-RF recruitment to the first intron of the TRE-*FXN* gene that is summarized in Figure 1G.

For several of the FXN-RFs, small molecule inhibitors are available, and the next experiments tested whether small molecule inhibitors, like RNAi knockdown, could

increase transcription of the TRE-*FXN* gene. To date, seven compounds have been tested: two EZH2 inhibitors (EPZ6438 and GSK126), the H3K9 methyltransferase inhibitor chaetocin (which targets SETDB1 and EHMT2/G9a), three HDAC inhibitors (LMK235, PCI-24781 and trichostatin A (TSA)), and a KDM5A inhibitor (KDM5Ai). The qRT-PCR results of Figure 1H show that treatment of FA(GM23404) iPSCs with any one of the small molecule FXN-RF inhibitors upregulated TRE-*FXN* transcription, resulting in FXN mRNA levels comparable to that observed in normal iPSCs. Upregulation of TRE-*FXN* transcription by three representative small molecule FXN-RF inhibitors was, as expected, dose dependent (Figure 1I). The immunoblot of Figure 1J shows that all small molecule FXN-RF inhibitors tested also increased frataxin to levels comparable to that observed in normal iPSCs. Analysis in a second FA iPSC line confirmed that all of the small molecule FXN-RF inhibitors tested upregulated TRE-*FXN* transcription in FA(GAA-intact) iPSCs, resulting in FXN mRNA levels comparable to, and in some cases even greater than, that observed in FA(GAA-excised) iPSCs (Figure 1K).

## **Example 2. Inhibiting FXN-RFs leads to De-Repression of *FXN* Expression in FA Post-Mitotic Neurons**

The next experiments asked whether inhibition of the same set of FXN-RFs would also upregulate transcription of the TRE-*FXN* gene in post-mitotic neurons, which is the cell type most relevant to FA. To derive post-mitotic FA neurons, FA(GM23404) iPSCs were stably transduced with lentiviral vectors over-expressing Neurogenin-1 and Neurogenin-2 to drive neuronal differentiation, according to published methods (Buskamp et al. 2014, *Mol Syst Biol* 10:760); for convenience, these cells are referred to herein as FA neurons. Neuronal differentiation was assessed and confirmed by staining with the neuronal marker TUJ1 (Figure 2A). As expected, the FA neurons were post-mitotic as evidenced by the lack of the mitotic marker phosphorylated histone H3 (Figure 2B). Treatment of FA neurons with an shRNA targeting any one of the 10 FXN-RFs upregulated TRE-*FXN* transcription (Figure 2C) and increased frataxin (Figure 2D) to levels comparable to that of normal neurons. Likewise, treatment of FA neurons with small molecule FXN-RF inhibitors also upregulated TRE-*FXN* transcription (Figure 2E) and increased frataxin (Figure 2F) to levels comparable to that of normal neurons.

It was next determined whether shRNA-mediated inhibition of FXN-RFs could ameliorate two of the characteristic mitochondrial defects of FA neurons: (1) increased levels of reactive oxygen species (ROS), and (2) decreased oxygen consumption. To

assay for mitochondrial dysfunction, FA neurons an FXN-RF shRNA or treated with a small molecule FXN-RF inhibitor were stained with MitoSOX, (an indicator of mitochondrial superoxide levels, or ROS-generating mitochondria) followed by FACS analysis. Figure 3A shows that FA neurons expressing an NS shRNA accumulated  
 5 increased mitochondrial ROS production compared to EZH2- or HDAC5-knockdown FA neurons. Figure 3B shows that FA neurons had increased levels of mitochondrial ROS production compared to normal neurons (Codazzi et al., (2016) Hum Mol Genet 25(22): 4847-485). Notably, inhibition of FXN-RFs in FA neurons restored mitochondrial ROS production to levels comparable to that observed in normal neurons. In the second set of  
 10 experiments, mitochondrial oxygen consumption, which is related to ATP production, was measured using an Agilent Seahorse XF Analyzer (Divakaruni et al., (2014) Methods Enzymol 547:309-54). Figure 3C shows that oxygen consumption in FA neurons was ~60% of the level observed in normal neurons. Notably, inhibition of FXN-RFs in FA neurons restored oxygen consumption to levels comparable to that observed in normal  
 15 neurons. Collectively, these preliminary results provide important proof-of-concept that inhibition of FXN-RFs can ameliorate the mitochondrial defects of FA post-mitotic neurons.

Mitochondrial dysfunction results in reduced levels of several mitochondrial Fe-S proteins, such as aconitase 2 (ACO2), iron-sulfur cluster assembly enzyme (ISCU) and  
 20 NADH:ubiquinone oxidoreductase core subunit S3 (NDUFS3), and lipoic acid-containing proteins, such as pyruvate dehydrogenase (PDH) and 2-oxoglutarate dehydrogenase (OGDH), as well as elevated levels of mitochondria superoxide dismutase (SOD2) (Urrutia et al., (2014) Front Pharmacol 5:38). Immunoblot analysis is performed using methods known in the art to determine whether treatment with an FXN-RF shRNA or a  
 25 small molecule FXN-RF inhibitor restores the normal levels of these mitochondrial proteins in FA neurons.

### **Example 3. Inhibiting FXN-RFs leads to De-Repression of *FXN* Expression in FA Cardiomyocytes**

The next experiments were performed to determine whether inhibition of the same  
 30 set of FXN-RFs would also upregulate transcription of the TRE-FXN gene in cardiomyocytes. To derive FA cardiomyocytes, a published method was used in which iPSCs are sequentially cultured in chemically defined media (Burridge et al., (2011) PLoS One 6(4): e18293). In brief, FA(GM23404) iPSCs were cultured for two days with

chemically defined medium (“CDM3”, consisting of RPMI 1640 medium, albumin and ascorbic acid) supplemented with the GSK3 $\beta$  inhibitor and Wnt signaling activator CHIR99021, then cultured for two days with CDM3 supplemented with the Wnt inhibitor Wnt-C59, and finally cultured with CDM3 alone. The colonies were dissociated and re-seeded to derive single cardiomyocytes. Cardiomyocyte differentiation occurred within 10-14 days and was assessed and confirmed by staining with the cardiomyocyte-specific markers cardiac troponin T and sarcomeric actinin (Dell'Era et al., (2015) World J Stem Cells 7(2): 329-42) (Figure 4A). Treatment of FA cardiomyocytes with an shRNA targeting any one of the 10 FXN-RFs upregulated TRE-FXN transcription (Figure 4B) and increased fraxatin (Figure 4C) to levels comparable to that of normal cardiomyocytes. Similarly, treatment of FA cardiomyocytes with small molecule FXN-RF inhibitors also upregulated TRE-FXN transcription (Figure 4D) and increased frataxin (Figure 4E) to levels comparable to that of normal cardiomyocytes.

Further experiments were performed to determine whether inhibition of FXN-RFs by shRNAs or small molecule inhibitors could, as in FA neurons (see Figures 3A-C), ameliorate characteristic mitochondrial defects of FA cardiomyocytes. Figure 5A shows, as expected, that FA cardiomyocytes had increased levels of mitochondrial ROS production compared to normal neurons [56]. Notably, inhibition of FXN-RFs in FA cardiomyocytes restored mitochondrial ROS production to levels comparable to that observed in normal cardiomyocytes. Figure 5B shows that oxygen consumption in FA cardiomyocytes was ~68% of the level observed in normal neurons. Notably, inhibition FXN-RFs in FA neurons restored oxygen consumption to levels comparable to that observed in normal neurons. Collectively, these preliminary results provide important proof-of-concept that inhibition of FXN-RFs can ameliorate the mitochondrial defects of FA cardiomyocytes.

Immunoblot analysis is also performed using methods known in the art to determine whether treatment with an FXN-RF shRNA or a small molecule FXN-RF inhibitor restores normal levels of mitochondrial proteins (e.g., ACO2, ISCU, NDUFS3, PDH, OGDH, SOD2) in FA cardiomyocytes.

#### **Example 4. Identification of Additional Small Molecule Inhibitors of FXN-RFs**

One of the major objectives in identifying FXN-RFs is to ultimately obtain small molecule FXN-RF inhibitors. As a complementary approach to the shRNA screens for

identifying new FXN-RFs, 70 small molecule compounds from the Epigenetics Targeted Library from Life Chemicals were screened. These compounds were chosen based on their predicted ability (based on a virtual docking and similarity search) to inhibit various classes of negative epigenetic regulators. The results, shown in Figure 6, identified 23  
5 compounds that upregulated transcription of the TRE-*FXN* gene. The structures of these compounds are shown in Figures 7A-F.

### OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and  
10 not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

**WHAT IS CLAIMED IS:**

1. A method of treating a subject having a disorder associated with a mutation in the FXN gene and having reduced expression of frataxin protein, the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of a FXN Repressing Factor (FXN-RF) selected from the group consisting of EZH2, EED, DNMT3A, DNMT3B, SETDB1, EHMT2/G9a, RING1B/RNF2, KDM5A, KDM5D, HDAC2, HDAC5, and SIRT7.
2. The method of claim 1, wherein the small molecule is a molecule shown in Table 1 or Figs. 7A-7F.
3. The method of claim 1, wherein the subject has Friedreich ataxia (FA).
4. A method of treating a subject having a disorder associated with a mutation in the FXN gene and having reduced expression of frataxin protein, the method comprising administering to the subject a therapeutically effective amount of an inhibitory nucleic acid that targets and specifically reduces expression of a FXN Repressing Factor (FXN-RF) selected from the group consisting of EZH2, EED, DNMT3A, DNMT3B, SETDB1, EHMT2/G9a, RING1B/RNF2, KDM5A, KDM5D, HDAC2, HDAC5, and SIRT7.
5. The method of claim 4, wherein the subject has Friedreich ataxia (FA).
6. The method of claim 4, wherein the inhibitory nucleic acid is a small interfering RNA, small hairpin RNA, or antisense oligonucleotide.
7. The use of a small molecule inhibitor of a FXN Repressing Factor (FXN-RF) selected from the group consisting of EZH2, EED, DNMT3A, DNMT3B, SETDB1, EHMT2/G9a, RING1B/RNF2, KDM5A, KDM5D, HDAC2, HDAC5, and SIRT7 in a method of treating a subject having a disorder associated with a mutation in the FXN gene and having reduced expression of frataxin protein.
8. The use of claim 7, wherein the small molecule is a molecule shown in Table 1 or Figs. 7A-7F.

9. The use of an inhibitory nucleic acid that targets and specifically reduces expression of a FXN Repressing Factor (FXN-RF) selected from the group consisting of EZH2, EED, DNMT3A, DNMT3B, SETDB1, EHMT2/G9a, RING1B/RNF2, KDM5A, HDAC2, HDAC5, and SIRT7 in a method of treating a subject having a disorder associated with a mutation in the FXN gene and having reduced expression of frataxin protein.
10. The use of claim 9, wherein the inhibitory nucleic acid is a small interfering RNA or antisense oligonucleotide.
11. The use of claims 7-10, wherein the subject has Friedreich Ataxia.
12. The method of claim 1 or use of claim 7, wherein the small molecule is an inhibitor of EZH2 (optionally EPZ6438, GSK126, F2880-2566; F5564-0146; F6235-0533; or F3407-3748); an inhibitor of SETDB1 and EHMT2 (optionally chaetocin); an inhibitor of KDM5A (optionally F3222-4242; F3358-0326; F3385-1519; HDM inhibitor, 2,4-PDCA; JIB04; KDM5Ai, 4-Carboxy-2-heterocyclic pyridine derivatives and pyrazole derivatives); an inhibitor of EED (optionally EED226 or A395); an HDAC inhibitor (optionally F0307-0365; F3407-0197; F6196-0976; F3095-0357; LMK235; PCI-24781; or trichostatin A (TSA)); an inhibitor of SUV39H1 (optionally F2470-0099; F2880-1734; or F3222-4478); an inhibitor of DNMT3A or DNMT3B (optionally F2578-0281; F3258-0176; or F3342-0131); or an inhibitor of SIRT7 (optionally F2721-0219; F3220-0531; F3220-0613; F3319-0778; or F3385-2786).




**FIG. 1A**




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E





FIG. 1F

6 / 24

*FIG. 1G*

7 / 24




FIG. 1H




FIG. 1I




FIG. 1J

9 / 24




FIG. 1K

TUJ1/DAPI




FIG. 2A

10 / 24




FIG. 2B




FIG. 2C



FIG. 2D




FIG. 2E

12 / 24




FIG. 2F




FIG. 3A




FIG. 3B




FIG. 3C

14 / 24




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 5A




FIG. 5B






FIG. 6


F2880-2566



F5564-0146



F3407-3748



F6235-0533






FIG. 7A

20 / 24

F3222-4478



F2880-1734



F2740-0099






FIG. 7B

F3385-1519



F3358-0326



F3222-4242






FIG. 7C


F0307-0365



F3407-0197



F6196-0976



F3095-0357






FIG. 7D

23 / 24

F3342-0131



F3258-0176



F2758-0281






FIG. 7E


F2721-0219




F3220-0531



F3220-0613



F3319-0778



F3385-2786




FIG. 7F

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/18181

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC(8) - A61K 31/4015, A61K 39/395, A61K 48/00 (2018.01)  
 CPC - A61K 48/00, C12Q 1/68, A61K 31/713

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History Document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History Document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History Document

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages                                                          | Relevant to claim No. |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X         | US 2016/0201063 A1 (RANA THERAPEUTICS, INC.) 14 July 2016 (14.07.2016) para [0010], [0049], [0057], [0060], [0061], [0178], [0216], Table 2 | 1-3, 7, 8, 12         |
| A         | WO 2015/023938 A1 (RANA THERAPEUTICS, INC.) 19 February 2015 (19.02.2015) p. 3-4.                                                           | 1                     |

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

25 April 2018

Date of mailing of the international search report

21 JUN 2018

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
 P.O. Box 1450, Alexandria, Virginia 22313-1450  
 Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300  
 PCT OSP: 571-272-7774

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/18181

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☒ Claims Nos.: 11  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

---please see continuation on extra sheet---

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-3, 7, 8, 12

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US 18/18181

Continuation of Box No. III Observations where unity of invention is lacking

Group I, claims 1-3, 7-8, 12 directed to use of a small molecule inhibitor of a FXN Repressing Factor (FXN-RF).

Group II, claims 4-6, and 9-10, directed to use of an inhibitory nucleic acid that targets and specifically reduces expression of a FXN-RF.

The inventions listed as Groups I-II do not relate to a single special technical feature under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special technical features:

Group I has the special technical feature of a small molecule inhibitor, that is not required by Group II.

Group II has the special technical feature of an inhibitory nucleic acid, that is not required by Group I.

Common technical features:

Groups I-II share the common technical feature of a method of treating a subject having a disorder associated with a mutation in the FXN gene and having reduced expression of frataxin protein, the method comprising administering to the subject a therapeutically effective amount of a inhibitor of a FXN-RF selected from the group consisting of EZH2, EED, DNMT3A, DNMT3B, SETDB1, EHMT2/G9a, RING1B/RNF2, KDM5A, KDM5D, HDAC2, HDAC5, and SIRT7; and use of said inhibitor for said treatment method. However, this shared technical feature does not represent a contribution over prior art, because this shared technical feature is anticipated by US 2016/0201063 A1 to Rana Therapeutics, Inc. (hereinafter Rana).

Rana teaches a method of treating a subject having a disorder associated with a mutation in the FXN gene and having reduced expression of frataxin protein, the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of the FXN Repressing Factor (FXN-RF) selected from the group consisting of EZH2, EED, DNMT3A, DNMT3B, SETDB1, EHMT2/G9a, RING1B/RNF2, KDM5A, KDM5D, HDAC2, HDAC5, and SIRT7 (para [0057] "In some embodiments, a cell having a lower level of FXN expression compared to an appropriate control level of FXN expression is a cell obtained from a subject having Friedreich's ataxia. A subject having Friedreich's ataxia can be identified, e.g., by the number of GAA repeats present in the first intron of an FXN gene of the subject... A genetic test, e.g., a PCR-based test, may be used to identify a subject having expanded GAA triplet repeats in the first intron of FXN"; para [0060] "In another aspect of the invention, methods comprise administering to a subject (e.g. a human) a composition as described herein (e.g., a composition comprising an oligonucleotide and/or inhibitor targeting a negative epigenetic regulator of FXN) to increase FXN protein levels in the subject."; para [0049] In some embodiments, provided are methods for increasing FXN expression in a cell by using one more inhibitors of histone-lysine N-methyltransferase In some embodiments, the inhibitor is a small molecule inhibitor." para [0010] "In some embodiments, the histone-lysine N-methyltransferase is ..., SETDB1, ..."; para [0216] "The concentration of the oligonucleotide or inhibitor composition is an amount sufficient to be effective in treating or preventing a disorder or to regulate a physiological condition in humans.").

As the technical features were known in the art at the time of the invention, they cannot be considered special technical features that would otherwise unify the groups.

Therefore, Group I-II inventions lack unity under PCT Rule 13 because they do not share the same or corresponding special technical feature.